Page last updated: 2024-11-12

tmc 353121

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11249932
CHEMBL ID408963
SCHEMBL ID540713
MeSH IDM0521400

Synonyms (26)

Synonym
tmc353121
HY-11097
cid 11249932
2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(4-morpholinyl)propyl]amino]-1h-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol
CHEMBL408963
857066-90-1
tmc-353121
538ebt31z1 ,
unii-538ebt31z1
CS-0682
tm-3
2-((6-(((2-(3-hydroxypropyl)-5-methylphenyl)amino)methyl)-2-((3-(morpholin-4-yl)propyl)amino)benzimidazol-1-yl)methyl)-6-methylpyridin-3-ol
3-pyridinol, 2-((6-(((2-(3-hydroxypropyl)-5-methylphenyl)amino)methyl)-2-((3-(4-morpholinyl)propyl)amino)-1h-benzimidazol-1-yl)methyl)-6-methyl-
SCHEMBL540713
DTXSID10235008
2-[[6-[[2-(3-hydroxypropyl)-5-methylanilino]methyl]-2-(3-morpholin-4-ylpropylamino)benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
c32h42n6o3
AKOS030526935
NCGC00379057-01
2-[[6-[[[2-(3-hydroxypropyl)-5-methylphenyl]amino]methyl]-2-[[3-(morpholin-4-yl)propyl]amino]benzimidazol-1-yl]methyl]-6-methylpyridin-3-ol
2-((6-(((2-(3-hydroxypropyl)-5-methylphenyl)amino)methyl)-2-((3-morpholinopropyl)amino)-1h-benzo[d]imidazol-1-yl)methyl)-6-methylpyridin-3-ol
Q27261082
A914642
F84821
MS-30170
NCGC00379057-02

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID317566Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 40 mg/kg, po 2 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317549Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV R2LO2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583659Clearance in Sprague-Dawley rat plasma at 10 mg/kg, iv administered as single bolus dose2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317539Antiviral activity against RSV CI42 replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317540Antiviral activity against RSV R1LO replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317562Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 5 mins prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317568Plasma clearance in Sprague-Dawley rat at 2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583660Volume of distribution at steady state in Sprague-Dawley rat plasma at 10 mg/kg, iv administered as single bolus dose2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583662Ratio of AUC (0 to 24 hrs) in Sprague-Dawley rat plasma to bronchoalveolar lavage fluid measured at 15 mins and 1 hr2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317536Antiviral activity against RSV Cl11 replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID1190754Resistance index, ratio of EC50 for drug resistant respiratory syncytial virus B1 expressing F protein L141F mutant to EC50 for wild type Respiratory syncytial virus B12015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.
AID583658AUC (0 to 24 hrs) in Sprague-Dawley rat bronchoalveolar lavage fluid at 10 mg/kg, iv administered as single bolus dose2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583684AUC (0 to 24 hrs) in Sprague-Dawley rat plasma at 10 mg/kg, iv administered as single bolus dose2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317545Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV CI572008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317542Antiviral activity against RSV R6LO replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317535Antiviral activity against RSV LO replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317533Cytotoxicity against human HeLaM cells by MTT assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317558Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 48 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583655Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 12.5 mg/kg, sc single dose administered 24 hrs before viral infection by qRT-PCR assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317573Absolute bioavailability in Sprague-Dawley rat plasma at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317572AUC (0 to infinity) in Sprague-Dawley rat plasma at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583683Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as maximum reduction in epithelial lining fluid viral load at 200 ng/ml plasma concentration2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317537Antiviral activity against RSV CI57 replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317548Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV R1LO2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317546Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV CI412008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583679Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 200 mg/kg, sc single dose administered 24 hrs before viral infection by plaque assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583677Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 50 mg/kg, sc single dose administered 24 hrs before viral infection by plaque assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317567AUC (0 to infinity) in Sprague-Dawley rat plasma at 2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583670Drug level in cotton rat plasma at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317559Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 24 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583673Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 100 mg/kg, sc single dose administered 24 hrs before viral infection by qRT-PCR assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317553Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 5 mg/mL by aerosol administration 1 hr prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317538Antiviral activity against RSV CI41 replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583676Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 25 mg/kg, sc single dose administered 24 hrs before viral infection by plaque assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317560Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 4 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317565Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, po 2 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317534Half life in Sprague-Dawley rat lung2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583657AUC (0 to 24 hrs) in Sprague-Dawley rat lung tissue at 10 mg/kg, iv administered as single bolus dose2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317541Antiviral activity against RSV R2LO replication in HeLa cells2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317569Volume of distribution in Sprague-Dawley rat plasma at 2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID1190756Resistance index, ratio of EC50 for VP-14637 resistant respiratory syncytial virus Long expressing F protein D489Y mutant to EC50 for wild type Respiratory syncytial virus B12015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.
AID583654Ratio of AUC (0 to 24 hrs) in Sprague-Dawley rat plasma to bronchoalveolar lavage fluid measured at 8 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317557Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 72 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317543Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV LO2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583666Drug level in Sprague-Dawley rat epithelial lining fluid at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317532Inhibition of RSV by MTT assay2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317550Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV R6LO2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317561Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 1 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583665Drug level in Sprague-Dawley rat bronchoalveolar lavage fluid at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583667Drug level in cotton rat epithelial lining fluid at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317563Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv after 3 hrs of viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583661Ratio of AUC (0 to 24 hrs) in Sprague-Dawley rat lung tissue to plasma2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317554Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 20 mg/mL by aerosol administration 1 hr prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583671Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 25 mg/kg, sc single dose administered 24 hrs before viral infection by qRT-PCR assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583674Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 200 mg/kg, sc single dose administered 24 hrs before viral infection by qRT-PCR assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583682Antiviral activity against respiratory syncytial virus long strain infected in Human HeLaM cells2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317555Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 2 mg/kg, iv 5 mins prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317570Half life in Sprague-Dawley rat plasma at 2 mg/kg, iv2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317556Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv 96 hrs prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583668Drug level in cotton rat bronchoalveolar lavage fluid at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317544Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV CI112008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID1190755Resistance index, ratio of EC50 for drug resistant respiratory syncytial virus Long expressing F protein Q494L mutant to EC50 for wild type Respiratory syncytial virus B12015Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4
1,2,3,9b-Tetrahydro-5H-imidazo[2,1-a]isoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: identification of BTA9881 as a preclinical candidate.
AID583664Drug level in Sprague-Dawley rat lung tissue at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583672Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 50 mg/kg, sc single dose administered 24 hrs before viral infection by qRT-PCR assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317571Cmax in Sprague-Dawley rat plasma at 10 mg/kg, po2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317564Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 10 mg/kg, iv after 24 hrs of viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317551Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 0.25 mg/mL by aerosol administration 1 hr prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583675Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 12.5 mg/kg, sc single dose administered 24 hrs before viral infection by plaque assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583669Drug level in cotton rat lung tissue at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID317547Selectivity index, ratio of CC50 for HeLaM cells to EC50 for RSV CI422008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID317552Antiviral activity in RSV infected cotton rat model assessed as log reduction of viral titer at 1.25 mg/mL by aerosol administration 1 hr prior to viral challenge2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
AID583656Drug level in cotton rat plasma at 12.5 - 200 mg/kg, sc administered as single dose measured after 24 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583663Drug level in Sprague-Dawley rat plasma at 10 mg/kg, iv administered as single bolus dose measured after 3 hrs2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID583678Antiviral activity against respiratory syncytial virus long strain infected in cotton rat assessed as log reduction in epithelial lining fluid viral load at 100 mg/kg, sc single dose administered 24 hrs before viral infection by plaque assay2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Pharmacokinetics-pharmacodynamics of a respiratory syncytial virus fusion inhibitor in the cotton rat model.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.90 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]